Doxorubicin hyaluronic acid complex

Drug Profile

Doxorubicin hyaluronic acid complex

Alternative Names: Doxorubicin hyaluronan acid complex; HA-doxorubicin; Hyaluronan doxorubicin complex; Hyaluronic acid + doxorubicin; Hyaluronic acid doxorubicin complex; HyDOX

Latest Information Update: 21 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Monash University
  • Class Anthracyclines; Cytostatic antibiotics; Doxorubicins; Small molecules
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Cancer

Most Recent Events

  • 19 Jul 2013 Biomarkers information updated
  • 07 Mar 2013 Suspended - Phase-I/II for Cancer (metastatic disease, treatment-resistant, late-stage disease) in Australia (IV)
  • 14 Aug 2003 Phase-I/IIa clinical trials in Cancer (metastatic disease, treatment-resistant, late-stage disease) in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top